Imatinib, a tyrosine kinase inhibitor (TKI) of BCR-ABL, was the standard first-line therapy for
chronic myeloid leukemia (CML) for almost 10 years. Dasatinib and nilotinib, two newer …

Beginning with imatinib a decade ago, therapy based on targeted inhibition of the BCR-ABL
kinase has greatly improved the prognosis for chronic myeloid leukemia (CML) patients. The …

Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development
of resistance continues to challenge the treatment of this disease. Mutations within the …

Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of
chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are …

Importance of the field: c-Src and Bcr-Abl are two non-receptor or cytoplasmic tyrosine
kinases (TKs) that play important roles in the development of solid and hematological …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder that affects 5000 new
patients per year in the United States. Prior to 10years ago, durable remission was rare and …

The treatment of chronic myeloid leukemia (CML) drastically changed with the introduction
of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), in 1998. By directly targeting …

Targeted therapy with the Abl kinase inhibitor imatinib has markedly improved the outlook
for patients with chronic myeloid leukemia (CML). Breakpoint cluster region (Bcr)-Abl …

Chronic myelogenous leukemia (CML) is a myeloproliferative disease associated with a
defined genetic abnormality, the Bcr‐Abl fusion gene on the Philadelphia chromosome that …

In patients with chronic myeloid leukemia (CML), disease in the initial chronic phase (CP)
and subsequent progression are driven by the oncogenic activity of the BCR–ABL fusion …